Additional ex vivo experiments using freshly isolated CSC-enriched cell populations from specific BRCA1 KO animals and primary breast tumor samples of distinct molecular subtypes should definitely clarify the role of the anti-RANKL antibody denosumab as a potential breast CSC-specific inhibitor. This evidence concerns the gene BRCA1 and breast neoplasm.